CLINICAL TRIALS PROFILE FOR RIST4721
✉ Email this page to a colleague
Clinical Trials for RIST4721
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT03988335 ↗ | A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) | Completed | Aristea Therapeutics, Inc. | Phase 2 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis |
NCT04105959 ↗ | A Study to Investigate the Effects of RIST4721 on the Inflammatory Response in Healthy Male Subjects Using a Blister Model | Completed | Aristea Therapeutics, Inc. | Phase 1 | A Randomised, Single-Blind, Placebo-Controlled, Crossover Study to Investigate the Effects of RIST4721, a Novel CXCR2 Inhibitor, on the Inflammatory Response in Healthy Male Subjects Using a Standardized Blister Model |
NCT05023811 ↗ | A Study of the ADME of [14C]RIST4721 in Healthy Male Subjects | Recruiting | Aristea Therapeutics, Inc. | Phase 1 | A Phase I, Open-label Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]RIST4721 Following a Single Oral Dose to Healthy Male Subjects |
NCT05194839 ↗ | A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) | Recruiting | Aristea Therapeutics, Inc. | Phase 2 | A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis |
NCT05348681 ↗ | A Study to Evaluate RIST4721 in Hidradenitis Suppurativa (HS) | Not yet recruiting | Aristea Therapeutics, Inc. | Phase 2 | A Randomized, Double-blinded, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Hidradenitis Suppurativa |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for RIST4721
Condition Name
Clinical Trial Locations for RIST4721
Trials by Country
Clinical Trial Progress for RIST4721
Clinical Trial Phase
Clinical Trial Sponsors for RIST4721
Sponsor Name